Shelton Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Shelton Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,429	Closed	-$587K	–	848
2018 Q3	$587K	Buy	3,429 +281	+9%	+$42.4K	0.03%	322
2018 Q2	$407K	Hold	3,148	–	–	0.03%	424
2018 Q1	$324K	Buy	3,148 +416	+15%	+$41.1K	0.02%	518
2017 Q4	$233K	Hold	2,732	–	–	0.02%	735
2017 Q3	$232K	Sell	2,732 -290	-10%	-$23K	0.02%	718
2017 Q2	$229K	Buy	+3,022	New	+$211K	0.02%	750

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Shelton Capital Management's LGND Position: Q4 2018 in Review

Shelton Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2018, closing a stake of 3,429 shares — an estimated $587K sold.

Shelton Capital Management first reported a position in LGND in Q2 2017 and held it in 6 quarters. The position peaked at $587K in Q3 2018. 362 funds tracked by Wall St. Rank hold LGND as of Q4 2018.

Shelton Capital Management reported no remaining Ligand Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Shelton Capital Management sold 3,429 Ligand Pharmaceuticals shares in Q4 2018, an estimated $587K.
Shelton Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2017 and held it in 6 quarters.
Shelton Capital Management's Ligand Pharmaceuticals position peaked at $587K in Q3 2018.
362 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2018.

Based on Shelton Capital Management's 13F filing for Q4 2018, filed 31 Jan 2019.